Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 24 of 24 matching drugs for FRK — including drugs targeting any of its 6 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab FRK Direct 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) FRK Direct 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FRK Direct 3
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment FRK Direct 2
regorafenib FRK Direct yes 2
regorafenib, laboratory biomarker analysis FRK Direct 2
afatinib, dasatinib, palbociclib, everolimus, olaparib FRK Direct 1
bevacizumab, dasatinib, placebo FRK Direct 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride FRK Direct 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method FRK Direct 1
dasatinib, laboratory biomarker analysis, physiologic testing FRK Direct 1
dasatinib, mfolfox6 FRK Direct 1
dasatinib, pharmacological study FRK Direct 1
dasatinib, temozolomide, placebo, radiation therapy FRK Direct 1
regorafenib, lomustine FRK Direct 1
regorafenib, nivolumab, capeox, folfox regimen FRK Direct 1
regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil FRK Direct 1
regorafenib, temozolomide FRK Direct 1
temozolomide, lomustine, regorafenib, radiation, paxalisib, val-083, vt1021, troriluzole, adi-peg 20 FRK Direct 1
dasatinib FRK Direct yes 0
vandetanib FRK Direct yes 0
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin TP53 SSL via TP53 1
dasatinib BLK SSL via BLK yes 0
vandetanib BLK SSL via BLK yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.